Chemotherapy can cause early menopause or infertility in women and have a profound negative impact on the quality of life of young female cancer survivors. Various factors are known to influence the risk of chemotherapy-induced ovarian failure, including the drug dose and treatment duration; however, the scheduling of dose administration has not yet been evaluated as an independent risk factor. We hypothesized that low-dose metronomic (LDM) chemotherapy scheduling would be less detrimental to ovarian function than the traditional maximum tolerated dose (MTD) strategy. In vitro, MTD cyclophosphamide exposure resulted in decreased proliferation and increased granulosa cell apoptosis, while cells treated with LDM cyclophosphamide were not different from untreated controls. Treatments of MTD cyclophosphamide induced high levels of follicle atresia and enhanced follicle recruitment in mice. In contrast, LDM delivery of an equivalent dose of cyclophosphamide reduced growing follicle numbers, but was not associated with higher levels of follicle atresia or recruitment. MTD cyclophosphamide induced significant vascular disruption and DNA damage in vivo, while LDM chemotherapy with equal cumulative amounts of cyclophosphamide was not different from controls. MTD chemotherapy also had a negative effect on mouse-fertility outcomes. Our findings suggest that LDM scheduling could potentially minimize the long-term effects of cyclophosphamide on female fertility by preventing follicle depletion from enhanced activation.
Introduction
Female cancer patients undergoing chemotherapy prior to the onset of menopause are put at risk of treatment-related infertility. Chemotherapeutics cause the destruction of tumor cells by interfering with cell cycle progression, which can also be detrimental to healthy dividing cells of the body. Many of the side effects of chemotherapy occur as a result of the targeting of normal proliferating cells, especially those of the bone marrow, gastrointestinal tracts, and hair follicles. Patients typically recover from these effects between chemotherapy cycles. However, the ovary contains cells that undergo repetitive proliferative cycles and the deleterious effects of chemotherapy can be cumulative and irreversible damage can occur even in the absence of obvious clinical signs. The consequence of chemotherapy could include infertility that occurs as a result of premature ovarian failure or irreparable damage to ovarian structures.
While cytotoxic killing of cancer cells is an obvious priority, it is important that women receive counseling about the impact of chemotherapy on fertility prior to the initiation of treatments. Studies have shown that cancer treatment-associated infertility can have a profound negative impact on the quality of life of female cancer survivors. Women with treatment-related infertility are more likely to report poorer mental health, and physical and psychological wellbeing than those without reproductive problems [1] . Current fertility preservation options include embryo, oocyte, or ovarian tissue cryopreservation. Ideally, these procedures should take place before the initiation of chemotherapy to optimize success; however, in many cases, cancer treatment cannot be postponed [2] . Various pharmacological interventions have been proposed to reduce the harmful effects of chemotherapy on ovarian function, but many of these techniques have yet to prove clinical efficacy. This emphasizes the need for better targeted cancer therapies that will have reduced effects on ovarian function and female fertility.
Conventional chemotherapy typically involves administration of the drug at a patient's maximum tolerated dose (MTD), followed by a drug-free interval to allow for recovery. The high levels of chemotherapy drug often result in significant side effects in the individual, and the drug-free interval has been associated with the development of chemotherapy resistance. However, despite these challenges, MTD chemotherapy remains the front line therapy for many cancers. More recently, cancer therapies have incorporated a different chemotherapy scheduling approach known as low-dose metronomic (LDM) chemotherapy. The term metronomic chemotherapy was coined by Dr Hanahan in reference to the musical instrument that produces consistent, metrical notes [3] . This scheduling approach involves more frequent (daily to weekly) administration of reduced chemotherapy doses, and decreased or absent drug-free intervals, which is thought to maintain constant chemotherapeutic pressure on the cancer cells. A number of clinical trials are currently evaluating the efficacy of LDM chemotherapy combined with targeted anti-angiogenic agents, since the pairing of these treatment strategies has been associated with additive or synergistic drug effects in a number of preclinical studies [4] [5] [6] .
Ovarian follicles and their supporting vasculature are believed to be targets of chemotherapy due to the rapid endothelial cell proliferation that occurs to facilitate follicular development during the ovarian cycle [7] . Primordial follicles may also be direct targets of chemotherapy, since cell cycle nonspecific cytotoxic agents, such as cyclophosphamide, can also be harmful to cells at rest [8] . Premature ovarian failure or early menopause results from accelerated depletion of the ovarian reserve, which could potentially be a consequence of direct primordial follicle damage or an indirect response to growing follicle loss [9] . In either case, follicular cell death or damage to the follicle-supporting vasculature may result as a consequence of systemic chemotherapy and may be implicated in the development of chemotherapy-associated infertility.
Cyclophosphamide belongs to the alkylating agent class of chemotherapy drugs and is used to treat a wide range of cancers. Cyclophosphamide has been studied for its effects on female reproductive function, and is associated with the highest risk of iatrogenic infertility following treatment of cancers common to women of reproductive age and children [10] . A delicate balance of inhibitory and stimulatory factors is responsible for maintaining primordial follicle dormancy and controlling their rate of activation for recruitment to the growing follicle pool. Cyclophosphamide may deplete the primordial follicle stockpile at an enhanced rate by directly promoting their activation, potentially through the P13K/PTEN/AKT pathway [11] , and also by destroying follicles in the process of growth development [12] .
In addition to drug type, factors that have been found to influence the risk of long-term ovarian damage include the cumulative dose received and the age of the patient at the time of exposure to chemotherapy. To date, the scheduling of chemotherapy administration has not been identified as an associated risk factor. This study was designed to test the hypothesis that LDM chemotherapy administration strategy is less detrimental to ovarian function than the traditional MTD strategy.
There is a proposed association between the use of chemotherapeutics and early menopause or infertility, and this association is thought to be attributed to long-term and repetitive damage of ovarian structures [13] . Factors that contribute degree of ovarian damage caused by chemotherapy drugs include: the drug dose, the number of treatment cycles endured, age at treatment, and the type of chemotherapeutic agent used. Alkylating agents have been identified as the most deleterious to female fertility and within this class, cyclophosphamide has been the most commonly studied for its harmful effects on female fertility [14] . This is likely due to its frequent use for the treatment of cancer in young females. Since the initial application of chemotherapeutics in cancer, MTD drug scheduling has most commonly been used due to its elevated toxicity to cancer cells. Recently, however, LDM chemotherapy has shown efficacy in inducing tumor cell death and also has been reported to have anti-angiogenic effects [15, 16] . As a widely useful and relatively inexpensive chemotherapeutic that can be delivered orally, cyclophosphamide has been the most commonly used drug for LDM scheduling [17] . Although LDM chemotherapy is associated with little to no short-term side effects, the long-term effects of this scheduling approach are currently unknown.
The goal of this study was to determine whether LDM chemotherapy had reduced negative effects on ovarian function and fertility, compared to MTD chemotherapy. The results from this study could have implications on chemotherapy treatment options for premenopausal women.
Materials and methods

In vitro model
Spontaneously immortalized rat granulosa cells (SIGCs) were generously provided by Dr R. Burghardt (Department of Anatomy, Texas A&M University, College Station, TX). Bovine granulosa cells (BGCs) were collected via follicle aspiration of slaughterhouse bovine ovaries as described previously [18] . Bovine aortic endothelial cells (BAECs) were collected from bovine thoracic aortas from slaughterhouse animals. Endothelial cells were scraped from the luminal surface of the aorta and digested for 15 min at 37
• C in M199 medium containing 25 mM HEPES, 27 mM NaHCO 3 , 100 µ/mL penicillin, 0.1 mg/mL streptomycin, 2.5 µg/mL fungizone, and 1 mg/mL collagenase. Cultured BAECs were verified as endothelial cells based on their ability to form a cobblestone appearance at confluence, and positive immunostaining for CD31. SIGCs were 
Western blotting
The in vitro model of LDM and MTD scheduling previously described was repeated in 10 cm culture dishes (seeding density: 75 000 cells; n = 3/group) using schedules that produced equivalent cumulative doses by the end of the treatment course (LDM-1000 nM/day; MTD-3000 nM/3 days). Protein was extracted from treated cells at 72 and 144 h. Cells were lysed over ice in an RIPA buffer, supplemented with fresh protease inhibitors, and protein concentrations were determined using a DC Bio-Rad Protein Quantification Kit (Bio-Rad). Equal-volume protein samples (n = 3/group), with a total of 50 or 40 μg of protein (for apoptosis and DNA damage analyses, respectively), were prepared in 3× reducing buffer containing DTT denaturing agent (Life Technologies Inc.) and heated to 90
• C for 5 min. Denatured samples were subjected to SDS-PAGE in a 12% separating gel and transferred to a nitrocellulose membrane (Ammersham Hybond ECL; GE Healthcare Bio-Sciences Corp., Piscataway, NJ). Membranes were blocked for 1 h in a solution of 5% (w/v) BSA in TBST and probed overnight at 4
• C for Cleaved Caspase-3
(1:500, Cell Signaling, cs9661) or Gamma-H2AX (1:1000; Abcam, ab11174) expression. The following day, membranes incubated in a 1:2000 dilution of HRP-conjugated secondary antibody for 1 h at room temperature. Antibody binding was visualized using Clarity Western ECL Substrate (Bio-Rad) and the Bio-Rad ChemiDoc XRS+ system. Densitometric analyses were performed using Bio-Rad Image Lab Software.
In vivo model
Six-week-old C57Bl6 mice (Charles River Laboratories; n = 45) were housed under standard conditions and with free access to food and water. All animal procedures were carried out in accordance with the guidelines of the Canadian Council on Animal Care. Mice were randomly assigned to LDM, MTD, or PBS (vehicle control) treatment groups (n = 15/group). Treatments were delivered as equal-volume intraperitoneal (IP) injections. Mice receiving MTD therapy received three doses of cyclophosphamide (100 mg/kg) at 6-day intervals as has been done by others [20] . In between MTD chemotherapy injections, the mice received daily 
Mating protocol
Four-week-old mice (n = 4/group) were subjected to the LDM and MTD injection protocols as described. Control mice were treated with vehicle alone. After the last injection, female mice were mated with untreated proven breeder male C57Bl6 mice. Mating was confirmed by the formation of a vaginal plug. The number of days until mating and the number of pups born per litter were quantified.
Morphometric analysis
Serial sectioned ovarian tissues were subjected to routine H&E staining. In each ovarian section, only follicles with a visible oocyte were quantified. All visible corpora lutea within a histological section were counted, including those from both current and previous cycles. Follicles were classified in stages defined by Myers et al. [21] . Primordial follicles consisted of an oocyte encapsulated by a single layer of entirely squamous granulosa cells and were counted as described in [21] . Average follicle numbers quantified by counting the number in each serial section and multiplying by 10 (as every 10th section was counted), according to established protocols [21] . Morphometric analyses were performed by one individual to eliminate interobserver variability. Follicles were considered activated, and therefore at the primary stage, if a single layer of granulosa cells surrounding the oocyte contained at least one cuboidal granulosa cell [22] . Secondary follicles had more than one layer of granulosa cells with no visible antrum. Follicles were classified as early antral if three or more granulosa cell layers were present with small areas of follicular fluid. Antral follicles were defined by a single large antral space, and in preovulatory follicles, the oocyte was surrounded by a clearly defined border of cumulus cells. For certain analyses, follicles were more broadly classified into preantral and antral groups, based on the presence or absence of antral space, respectively. Follicles were considered atretic when two or more of the following characteristics could be observed within a single section: a degenerating or absent oocyte, two or more pyknotic granulosa cell nuclei, disorganized granulosa cell layers that appear to be pulling away from the basement membrane, and folding of the zona pellucida [23, 24] . Zona pellucida remnants (ZPRs) were also quantified as an indication of late follicle atresia, which resembles collapsed eosinophilic bands within the ovarian stroma [21, 25] . The total ratios of growing to atretic follicles (excluding ZPRs) during the estrous cycle for each mouse were calculated by combining the counts from each time point of tissue collection.
Immunohistochemistry
Immunohistochemistry was performed as has been reported previously [6, [26] [27] [28] . Briefly, tissue sections were deparaffinized in xylene and rehydrated in decreasing concentrations of ETOH (100%, 90%: 2 × 2 min, 70%: 1 × 2 min). Endogenous peroxidase activity was quenched with immersion in a 1% (v/v) solution of H 2 O 2 in PBS. Antigen retrieval was performed with freshly prepared citrate buffer at 90
• C for 12 min. Tissues were blocked with 5% BSA/0.1% sodium azide and then probed overnight with either anti-Ki67 (1:200, Abcam, ab15580), anti-Cleaved Caspase-3 (1:100, Cell Signaling, cs9661), or anti Gamma-H2AX (1:200, Abcam Ab11174) primary antibody at 4
• C in a humidified chamber.
Tissues were then incubated in anti-rabbit biotinylated secondary antibody (1:100 dilution) for 2 h at room temperature, followed by a 1:50 dilution of avidin and biotinylated HRP (ExtrAvidinPeroxidase; Sigma-Aldrich), also at room temperature. Antibody immunolocalization was visualized by applying a fresh DAB solution (10 mg tablet, Sigma-Aldrich, in 5 mL RO water) to the tissue for 30 s. Carazzi's Haematoxylin was used as a counterstain and tissues were dehydrated and mounted on glass slides with Cytoseal-XYL mounting medium (Thermo Fisher Scientific, Nepean, ON). Images were captured on a BX-61 Olympus Microscope using Metamorph software (Metamorph, Burlingame, CA).
Statistical analysis
GraphPad Prism software was used for statistical analysis and graph preparation. Each in vitro treatment group was represented by at least three biological replicates (repeated in triplicate) in all experiments. Data from the in vitro model were analyzed using a one-way ANOVA, and a Tukey's test was used to determine statistical differences among treatment group means. A two-way ANOVA was performed for in vivo data and was also followed by a Tukey's post hoc test. Differences among treatment groups were considered significant if P < 0.05.
Results
Effect of low-dose metronomic and maximum tolerated dose chemotherapy on granulosa cell viability Scheduling of chemotherapy delivery had distinct effects on granulosa and endothelial cell viability. SIGCs, BGCs, and BAECs were treated for 72 or 144 h with cyclophosphamide (4HC) delivered with LDM or MTD scheduling and subjected to the WST-1 cell viability assay. 4HC delivered with metronomic scheduling did not affect granulosa or endothelial cell viability, except at the highest dose (1000 nM/day) ( Figure 1 ). Cells exposed to 4HC at MTD scheduling had significantly (P < 0.05) lower viability than controls and all LDM treatment groups ( Figure 1 ).
Low-dose metronomic and maximum tolerated dose chemotherapy effects on granulosa cell proliferation and apoptosis
Chemotherapy drugs delivered via MTD scheduling reduce proliferation and increase apoptosis in granulosa cells. SIGCs and BGCs were treated with 4HC for 72 and 144 h as in the viability experiments, and were subjected to IF staining for phosphorylated Histone H3 to measure cellular proliferation. After 72 h of treatment, SIGCs treated with MTD scheduling had significantly (P < 0.01) lower proliferation than cells either treated with PBS or LDM drug scheduling ( Figure 2 ). MTD chemotherapy in BGCs caused significant (P < 0.01) reduction in cell proliferation at both the 72 and 144 h timepoints ( Figure 2) . Following 144 h of treatment, cells were subjected to Western blot (WB) and IF analysis for active Caspase-3 as a marker of apoptosis. LDM chemotherapy resulted in a significant (P < 0.05) increase in active Caspase-3 expression compared to controls ( Figure 3A ), while MTD treatment increased active Caspase-3 expression compared to control and LDM treatments (P < 0.01) Downloaded from https://academic.oup.com/biolreprod/article-abstract/97/3/449/4097578 by OUP site access user on 08 October 2018 Figure 1 . Granulosa and endothelial cell viability after LDM and MTD treatment schedules of 4HC. A WST-1 assay was used to measure SIGC, BGC, and BAEC viability after 72 and 144 h of 4HC treatments. Cell viability is presented as a percentage of PBS controls. At 72 and 144 h, equivalent cumulative doses (3000 nM at 72 h/6000 nM at 144 h) were administered by LDM and MTD schedules (LDM: 1000 nM/day; MTD: 3000 nM/3 days). Significance was determined by one-way ANOVA followed by Tukey's multiple comparison test. Asterisks directly above bars and lines represent statistical significance relative to PBS and LDM treatment, respectively ( * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001). Error bars represent standard error (n = 6/treatment group).
( Figure 3A ). LDM treatment resulted in an increase (P < 0.05) in the percentage of active Caspase-3 positive cells ( Figure 3C ) while MTD chemotherapy significantly increased (P < 0.01) the percentage of active Caspase-3 positive SIGCs ( Figure 3C ). IF was also conducted on BGCs at 144 h, and LDM chemotherapy caused an increase (P < 0.01) in the percentage of immunopositive cells ( Figure 3C ) while MTD treatment caused an increase (P < 0.001) in active Caspase-3 positive cells ( Figure 3C ). Asterisks directly above bars and lines represent statistical significance compared to PBS and LDM treatment, respectively ( * P < 0.05; * * P < 0.01; * * * P < 0.001).
Significance was determined by one-way ANOVA followed by Tukey's multiple comparison test. Error bars represent standard error.
DNA damage induced by low-dose metronomic and maximum tolerated dose chemotherapy Significance was determined by one-way ANOVA followed by Tukey's multiple comparison test. Error bars represent standard error ( * P < 0.05; * * P < 0.01; * * * P < 0.001).
and the number of positive foci per cell were counted. Both LDM and MTD treatments caused an increase in the number of cells with γ H2AX positive nuclei ( Figure 4E ) as well as the number of foci ( Figure 4F ), compared to controls. MTD treatment resulted in a significantly (P < 0.001) higher proportion of positive cells and number of foci compared to both the control and LDM treatment groups ( Figure 4E and F) .
In vivo folliculogenesis following low-dose metronomic and maximum tolerated dose chemotherapy treatments
Mice were treated with LDM or MTD chemotherapy, or received PBS injections as control as described above. Following ovarian synchronization, tissues were collected at the preantral, antral, ovulatory, early luteal, and luteal phases of the ovarian cycle. and follicles were quantified based on their stage of development within the ovary. MTD chemotherapy treatment resulted in significant reduction in primary and preantral follicles, and a significant increase in atretic follicles at the preantral phase of the ovarian cycle compared to control and LDM groups ( Figure 5A ). At the antral phase of the ovarian cycle, MTD chemotherapy resulted in an increase in the number of secondary and atretic follicles, compared to the LDM treatment ( Figure 5A ). However, no differences were noted in numbers of follicles classified as early antral or antral. MTD chemotherapy caused a significant reduction in the number of primary and preantral follicles in the early luteal phase of the cycle. At the luteal phase of the ovarian cycle, MTD treatment resulted in a significant increase in the number of atretic follicles, compared to the control and LDM treatment groups ( Figure 5A ). MTD chemotherapy resulted in a significant (P < 0.01) decrease in the number of primordial follicles compared to PBS controls and LDM-treated mice ( Figure 5B ). Ovarian morphology was altered in MTD chemotherapy treated mice. Histological sections obtained at the antral stage of the ovarian cycle demonstrated disrupted ovarian morphology, with smaller ovarian size, fewer antral follicles, and increased follicles with atretic features (arrows) ( Figure 5C ). There was a significant (P < 0.05) reduction in ovarian weight in MTD chemotherapy treated mice at the antral phase of the cycle, compared to control or LDM-treated mice ( Figure 5D ). Significance was determined by two-way ANOVA followed by Tukey's multiple comparison test. Error bars represent standard error (n = 3 mice/treatment group) ( * P < 0.05; * * P < 0.01; * * * P < 0.001). Ovarian follicle morphology changes following low-dose metronomic and maximum tolerated dose chemotherapy treatments
Compared to control or LDM treatment, MTD therapy resulted in an increased proportion of atretic follicles at the preantral, antral, and ovulatory phases of the ovarian cycle ( Figure 6A ). Throughout the course of follicle development, MTD therapy resulted in a reduced ratio of healthy:atretic follicles (P < 0.01), while LDM therapy was not different from controls ( Figure 6B ). Neither LDM nor MTD therapy resulted in a change in the number of corpora lutea, compared to PBS-treated controls ( Figure 6C ).
Granulosa cell proliferation and apoptosis following low-dose metronomic and maximum tolerated dose chemotherapy treatments
At various phases of the ovarian cycle, ovaries were collected from mice and subjected to immunohistochemistry for Ki67 and Cleaved Caspase-3 to quantify changes in proliferation and apoptosis, respectively. At the ovulatory phase of the cycle, MTD chemotherapy induced a significant (P < 0.05) increase in granulosa cell proliferation, compared to mice treated with PBS or LDM chemotherapy ( Figure 7A ). In the early luteal phase, LDM chemotherapy increased the percent of ovarian granulosa cells immunopositive for Ki67 (P < 0.05) ( Figure 7A ). With respect to apoptosis, MTD chemotherapy induced a significant increase in the percentage of granulosa cells immunopositive for Cleaved Caspase-3 at the preantral and ovulatory phases of the cycle ( Figure 7B ). LDM chemotherapy did not result in an incidence of apoptosis different from controls at any phase of the ovarian cycle ( Figure 7B ).
Granulosa cell DNA damage following treatment with low-dose metronomic and maximum tolerated dose chemotherapy
Fixed ovaries from mice collected at the preantral and antral phases of the cycle were immunostained for γ H2AX to identify the proportion of granulosa cells that had DNA damage as a result of LDM or MTD chemotherapy. Control mice treated with PBS exhibited few cells immunopositive for Gamma-H2AX. LDM chemotherapy resulted in an increase in γ H2AX positive granulosa cells at the antral phase of the cycle, compared to PBS controls. MTD chemotherapy induced a greater number of granulosa cells positive for the marker of DNA damage compared to PBS controls and LDM-treated mice (P < 0.01) (Figure 8 ).
Changes in ovarian blood vessel density following low-dose metronomic and maximum tolerated dose chemotherapy treatment regimens
Tissues collected from the antral phase of the ovarian cycle were immunostained with an antibody against CD31 to visualize endothelial cells. MTD chemotherapy resulted in a significant (P < 0.05) reduction in the proportion of tissue comprised of blood vessel ( Figure 9 ). Mice treated with LDM chemotherapy had ovarian blood vessel density similar to PBS-treated controls ( Figure 9 ). Three images were captured per mouse ovarian section (n = 9 images analyzed/treatment group). Significance was determined by two-way ANOVA followed by Tukey's multiple comparison test. Error bars represent standard error. (B) Ovaries were immunostained for Cleaved Caspase-3 to detect follicle cell apoptosis at the preantral and ovulatory phases of the ovarian cycle. Areas with the highest proportion of positively stained nuclei were imaged at 600× magnification; scale bar 25 μM. Three images were captured per mouse ovarian section (n = 9 images analyzed/treatment group). Significance was determined by two-way ANOVA followed by Tukey's multiple comparison test. Error bars represent standard error ( * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001). The proportion of γ H2AX positive granulosa cells were quantified. Asterisks demonstrate significant differences compared to other treatment groups within the same stage of the ovarian cycle. Significance was determined by one-way ANOVA followed by Tukey's multiple comparison test. Error bars represent standard error ( * P < 0.05; * * P < 0.01).
Downloaded from https://academic.oup.com/biolreprod/article-abstract/97/3/449/4097578 by OUP site access user on 08 October 2018 Figure 9 . Ovarian blood vessel density after LDM and MTD scheduling of cyclophosphamide in mice. Cryosections of ovarian tissue were stained for CD31 by IF at the preantral stage follicle development. Five images were captured per mouse ovarian cryosection (n = 15 images analyzed/treatment group) at 400× magnification. Blood vessels are pseudocolored red, and are overlaying a blue DAPI nuclear stain. Blood vessel density is expressed as vessel area over the total tissue area. Significance was determined by one-way ANOVA followed by Tukey's multiple comparison test. Error bars represent standard error ( * P < 0.05).
Changes in fertility following low-dose metronomic and maximum tolerated dose chemotherapy treatments in vivo
In vivo experiments were conducted to determine the effects of LDM and MTD chemotherapy on fertility. LDM treatment did not result in fertility outcomes different from controls ( Figure 10 ). MTD chemotherapy treatment resulted in a significant (P < 0.05) increase in the number of days to successful mating and resulted in a significant (P < 0.05) decrease in the number of pups born per litter ( Figure 10 ).
Discussion
This study has identified the scheduling of drug administration as a factor that could influence the risk of ovarian dysfunction associated with chemotherapy. Our data suggest that cyclophosphamideinduced ovarian damage that can contribute to early reproductive failure may be reduced if delivered at a more frequent low-dose schedule.
There has been an established association between the use of chemotherapeutics and early menopause or infertility as a result of long-term ovarian damage [13] . Chemotherapy drugs used to target cancer cells can also damage other cells that have high proliferative rates, such as follicular and luteal cells within the ovary [29] . Factors that contribute to the degree of ovarian damage caused by chemotherapy drugs include: the drug dose, the number of treatment cycles endured, age at treatment, and the type of chemotherapeutic agent used. Due to its frequent use for the treatment of cancers in young females, cyclophosphamide has been the most commonly studied for its harmful effects on female fertility [14] . Since the initial application of chemotherapeutics in cancer, MTD drug scheduling has been thought to be the most efficacious with respect to tumor cell death despite its associated toxicity [30] . Recently, however, administration of chemotherapy drugs at LDM doses have been shown to elicit both anti-angiogenic and anti-tumor effects [15, 16] . As a widely useful and relatively inexpensive chemotherapeutic that can be delivered orally, cyclophosphamide is the most commonly used drug for LDM scheduling [17] . Although LDM chemotherapy is associated with reduced short-term side effects, the long-term effects of this scheduling approach are currently unknown. We compared the effects of LDM and MTD chemotherapy schedules on ovarian function, with in vitro and in vivo models. Ovarian cells and ovarian tissue were exposed to equivalent cumulative doses of cyclophosphamide with both LDM and MTD scheduling. Similar drug proportions are used for LDM and MTD chemotherapy in mouse cancer treatment models. In the literature, metronomic schedules of cyclophosphamide range from 10 to 25 mg/kg per day [31] , while MTD schedules in mice generally consist of 105 to 150 mg/kg treatments on days 1, 3, and 5 of a 21-day cycle [32, 33] . The total doses for these optimized cyclophosphamide treatment schedules would be 315-420 mg/kg and 420 mg/kg for the LDM and MTD approaches, respectively. Thus, the total amount of cyclophosphamide administered by LDM and MTD schedules in mice are comparable, as they are in humans, over a constant length of time. For our study, in order to determine whether or not the scheduling of cyclophosphamide administration can influence ovarian function, the total amount of drug received by our mice needed to be roughly the same during the timepoints of follicle development. While conventional LDM and MTD treatments with cyclophosphamide utilize similar amounts of drug over a fixed period of time, the short estrous cycle of the mouse complicates the short-term analysis of the schedules effects on ovarian function. In the time it would take for LDM-treated mice to receive the same total dose used in a single MTD cycle, the ovaries of MTD-treated mice could potentially have undergone multiple cycles of follicle development and be replenished by a completely new population of growing follicles by the time of analysis [34] . Since LDM cyclophosphamide typically involves a 3-week period of rest, women of reproductive age will receive at most one dose of chemotherapy during a single menstrual cycle. To model this exposure in mice, which have a 4-6-day estrous cycle, a relatively high, but nonsterilizing [35] , dose of cyclophosphamide (100 mg/kg) was administered once every 6 days for a total of 2.5 chemotherapy 'cycles'. Chemotherapy schedules with cyclophosphamide were modeled in vitro on rodent and BGCs, and in vivo using 6-week old, sexually mature, female C57Bl/6 mice.
In vitro, exposure of SIGCs and BGCs to MTD levels of cyclophosphamide resulted in a significant reduction in cell proliferation and concomitant increase in granulosa cell DNA damage and apoptotic cell death compared to LDM cyclophosphamide treatment or controls, even though the cells were exposed to the same amount of drug over time. MTD chemotherapy has been shown to inhibit ovarian follicle cell growth and function [36] [37] [38] [39] , while the effects of LDM chemotherapy on noncancerous cells in vitro has not been studied. Granulosa cells exposed to chemotherapy drugs in vitro undergo high levels of apoptosis [40, 41] , and granulosa cell apoptosis is a leading contributor to premature ovarian failure in women [42, 43] . These in vitro data suggest that while MTD chemotherapy has an anti-proliferative and proapoptotic effect on ovarian granulosa cells, LDM chemotherapy has minimal effect on granulosa cell function.
Follicle counts revealed significant differences in preantral follicle numbers in mouse ovaries exposed to cyclophosphamide chemotherapy. The primary follicle population was initially reduced shortly after MTD cyclophosphamide in the preantral phase of the cycle. In the antral phase of the cycle, MTD chemotherapy resulted in increased proportion of cells progressing from the primary phase into secondary and preantral stages. The majority of these developing follicles became atretic, as indicated by the higher follicle atresia seen in the MTD treatment group, compared to LDM or controls. This may be a contributing mechanism to the follicle exhaustion seen following MTD cyclophosphamide chemotherapy [44] . In contrast, ovaries of LDM-treated mice displayed similar follicle dynamics to control mice despite the presence of fewer follicles at the initial stages. The LDM ovaries also appeared to have a smaller growing follicle population throughout the remaining stages, but the high variability of the control group did not allow this difference to be detected. Interestingly, the average preantral follicle count in the LDM treatment group was much less variable. This could be indicative of reduced competition during follicle selection as a result of decreased follicle numbers, since it was also found that both LDM and control ovaries had the same ratio of early growing to atretic follicles. Conversely, the proportion of atretic follicles was significantly higher in ovaries of MTD-treated mice during this ovarian cycle compared to the other treatment groups. Increased follicle atresia was measured immediately after MTD chemotherapy exposure and was consistent with levels reported in a recent dose-response trial of MTD cyclophosphamide exposure in mice [7] . In our in vivo model, ovarian synchronization was achieved with IP injections of PMSG and hCG, which allowed us to evaluate the effect of chemotherapy dosing regimens on ovarian structures at specific timepoints in the ovarian cycle. However, it must be acknowledged that the use of these gonadotropins to regulate the ovarian cycle may have impacted the follicular and luteal response to the chemotherapy drugs. It has been reported that following PMSG and hCG induced ovarian synchronization, that traditionally cytotoxic chemotherapy compounds had minimal apoptotic effect on terminally differentiated granulosa cells or luteal cells, but preferentially affected proliferative granulosa cells [45] . The specific effects of PMSG and hCG on chemotherapy response were not identified in this study, but it is possible that they had some impact on granulosa cell function in vivo.
An increase in growing follicle numbers in response to MTD cyclophosphamide has been previously documented in the literature. In fact, over four decades ago it was reported that a single 50 mg/kg dose of cyclophosphamide causes superovulation in mice 100 h after administration [46] . In another mouse study, following an initial decline in growing follicles triggered by a single 200 mg/kg dose of cyclophosphamide, there was a greater number of both preantral and antral follicles relative to controls 7 days after treatment [47] . More recently, a high number of small growing follicles were detected in mouse ovaries 3 days after a single 150 mg/kg exposure to cyclophosphamide [11] . This wave of follicle recruitment was correlated with a decrease in the ovarian reserve that could not be attributed to direct primordial follicle damage based on TUNEL staining for apoptosis. Therefore, it was proposed that cyclophosphamide-induced ovarian damage was primarily a consequence of a primordial follicle burnout effect through increased follicle activation and loss [11] . Enhanced follicle activation can be explained by various potential mechanisms, since a delicate balance of inhibitory and stimulatory factors is responsible for maintaining primordial follicle dormancy and the controlled activation and recruitment to the growing follicle population. The rate of follicle activation can be influenced by Downloaded from https://academic.oup.com/biolreprod/article-abstract/97/3/449/4097578 by OUP site access user on 08 October 2018 the growing follicle population, which actively secrete suppressive factors such anti-Müllerian hormone (AMH). AMH is produced by granulosa cells of primary to small antral follicles and has an inhibitory effect on follicle activation [48] . Decreased levels of AMH due to an acute loss of small follicle numbers may, therefore, stimulate increased primordial follicle recruitment to the growing follicle pool. Interestingly, we did not see an increase in follicle recruitment during continuous LDM exposure of the drug, although there was a significant reduction in small follicles. It has also been proposed that cyclophosphamide could be capable of depleting the ovarian reserve by directly promoting the PI3K/PTEN/Akt pathway responsible for primordial follicle activation [11] . This hypothesis may help provide an explanation for the lack of follicle recruitment after LDM cyclophosphamide treatments, as low doses may not be sufficient for direct follicle activation.
The follicle burnout effect could explain why MTD mice did not experience a reduction in successful ovulations based on luteal numbers, despite increased follicle atresia. In another study, corpora lutea numbers varied depending on the time point of tissue collection after MTD treatment. Following 75 mg/kg treatments of cyclophosphamide in mice, they actually discovered an increase in corpora lutea after 7 days [47] . Variability in corpora lutea numbers is likely related to the fluctuations in follicle numbers in response to intermittent MTD drug delivery.
Taken together, our findings suggest that MTD chemotherapy is associated with enhanced follicle wasting through increased follicle recruitment and subsequent atresia. However, this does not appear to be a mechanism of LDM-induced follicle loss.
Following 2 weeks of LDM cyclophosphamide, our mice displayed a reduction in growing follicles, but the relative proportions of each growing follicle type were unchanged compared to follicle populations sizes in untreated mice. Our findings are consistent with another recent report that mice exposed cyclophosphamide by a metronomic-like schedule (eight treatments of 50 mg/kg on alternate days) have fewer follicles at both 3 days, and 1 week posttreatment [7] . We also found that follicle atresia was reduced, but still proportional, to the size of the growing ovarian follicle population of LDM-treated mice. Interestingly, luteal quantification did not indicate that the effects of LDM chemotherapy influence the total number of successful ovulatory events. Overall, it appears that LDM cyclophosphamide has the opposite short-term effect on ovarian follicle development compared to MTD cyclophosphamide based on our morphometric analysis, since both follicle numbers and atresia were reduced by LDM chemotherapy, but increased by MTD chemotherapy. In contrast, ovaries of rats that had been given LDM cyclophosphamide (5 mg/kg/day) for a longer treatment length of 6 weeks were found to have a greater number of medium and large follicles relative to controls [44] . These observations are somewhat surprising considering LDM chemotherapy is anti-angiogenic and the fact that larger follicles are dependent on angiogenesis for survival, but could perhaps be an indication of slowed follicle growth during antral follicle development, which has previously been reported after administration of an anti-angiogenic drug in primates [49] . Existing studies, including our own, have only demonstrated short-term effects of LDM chemotherapy on the ovary and it remains unclear as to how these effects translate to long-term damage and fertility outcome compared to MTD scheduling.
We measured ovarian blood vessel density 24 h after exposure to LDM and MTD chemotherapy using CD31 as an indicator of mature blood vessels. There was a decrease in blood vessel density in ovarian sections exposed to MTD chemotherapy compared to PBS-and LDM-treated ovaries. Although vascular endothelial cells are considered the main targets for LDM chemotherapy, the mean ovarian vessel density of our LDM-treated mice was similar to the controls. In cancer chemotherapy, LDM scheduling is thought to have an antiangiogenic effect, although we did not see a change in vascular density in our mouse model. Metronomic chemotherapy preferentially affects the abnormal, immature blood vessels that predominate in solid tumors [50] . In our model, ovarian blood vessels were forming physiologically and likely were less affected by the anti-angiogenic effects of LDM chemotherapy than tumor vasculature. Also, from a technical perspective, the use of CD31 staining was previously reported to underestimate vascular damage by chemotherapy, since it was demonstrated that the endothelial cell lining of large blood vessels can be preserved despite clear evidence of vascular damage in ovaries of women exposed to chemotherapy [51, 52] .
We had expected the anti-angiogenic schedule to be more damaging to the ovarian vasculature, but our findings and existing evidence in the literature suggest that MTD chemotherapy has a greater negative effect on ovarian angiogenesis and the stromal vasculature than LDM chemotherapy. Visualization of newly formed blood vessels using CD34 staining allows detection of the microvasculature within the theca layer as early as the antral stage of follicle development as well as in the developing corpus luteum [53] . Recently, Ezoe and associates evaluated chemotherapy-induced vascular damage based on CD34 positive staining in follicles and corpora lutea after exposure to increasing doses of cyclophosphamide in mice [7] . They measured a dose-dependent decline in CD34 positive cells in developing follicles and luteal structures with MTD administration of the drug. Consistent with our CD31 data, the reduction in CD34 positive cells was greater after MTD scheduling than when the equivalent dose administered by LDM chemotherapy. Current evidence therefore suggests that MTD chemotherapy schedules of cyclophosphamide are actually more detrimental to both mature and developing blood vessels of the ovary than LDM schedules.
In conclusion, we have shown that the ovarian effects of cyclophosphamide chemotherapy are schedule dependent, and overall, MTD chemotherapy causes a greater disruption of normal ovarian function than LDM scheduling. Long-term damage needs to be evaluated in order to determine how these short-term scheduling effects impact fertility, but these data suggest that dose scheduling may be an important consideration in the chemotherapy regimen of reproductive-age women undergoing treatment.
